152 related articles for article (PubMed ID: 36127509)
41. Point-of-care CAR T-cell therapy as salvage strategy for out-of-specification tisagenlecleucel.
Fried S; Shouval R; Varda-Bloom N; Besser MJ; Yerushalmi R; Shem-Tov N; Danylesko I; Jacoby E; Teihman S; Itzhaki O; Fein JA; Kedmi M; Shimoni A; Nagler A; Avigdor A
Leuk Lymphoma; 2022 Dec; 63(14):3385-3393. PubMed ID: 36111694
[TBL] [Abstract][Full Text] [Related]
42. Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients - a matched control multicenter cohort study.
Ram R; Grisariu S; Shargian-Alon L; Amit O; Bar-On Y; Stepensky P; Yeshurun M; Avni B; Hagin D; Perry C; Gurion R; Sarid N; Herishanu Y; Gold R; Glait-Santar C; Kay S; Avivi I
Haematologica; 2022 May; 107(5):1111-1118. PubMed ID: 34233446
[TBL] [Abstract][Full Text] [Related]
43. Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients.
Cook MR; Dorris CS; Makambi KH; Luo Y; Munshi PN; Donato M; Rowley S; Saad A; Goy A; Dunleavy K; Ali A
Blood Adv; 2023 Jan; 7(1):32-39. PubMed ID: 36260735
[TBL] [Abstract][Full Text] [Related]
44. At The Bedside: Clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies.
Oluwole OO; Davila ML
J Leukoc Biol; 2016 Dec; 100(6):1265-1272. PubMed ID: 27354412
[TBL] [Abstract][Full Text] [Related]
45. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
46. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y
Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805
[TBL] [Abstract][Full Text] [Related]
47. [Analysis on poor efficacy factors in the treatment of recurrent/refractory B-cell lymphoma with CD19 CAR-T cells].
Xiao X; Yuan T; Meng JX; Jiang YY; Cao YQ; Li Q; Sun R; Zhao MF
Zhonghua Yi Xue Za Zhi; 2020 Mar; 100(8):593-598. PubMed ID: 32164113
[No Abstract] [Full Text] [Related]
48. Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma.
Yan ZX; Li L; Wang W; OuYang BS; Cheng S; Wang L; Wu W; Xu PP; Muftuoglu M; Hao M; Yang S; Zhang MC; Zheng Z; Li J; Zhao WL
Clin Cancer Res; 2019 Dec; 25(23):6995-7003. PubMed ID: 31444250
[TBL] [Abstract][Full Text] [Related]
49. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
[TBL] [Abstract][Full Text] [Related]
50. Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma.
Maloney DG; Kuruvilla J; Liu FF; Kostic A; Kim Y; Bonner A; Zhang Y; Fox CP; Cartron G
J Hematol Oncol; 2021 Sep; 14(1):140. PubMed ID: 34493319
[TBL] [Abstract][Full Text] [Related]
51. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
52. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.
Anagnostou T; Riaz IB; Hashmi SK; Murad MH; Kenderian SS
Lancet Haematol; 2020 Nov; 7(11):e816-e826. PubMed ID: 33091355
[TBL] [Abstract][Full Text] [Related]
53. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Locke FL; Ghobadi A; Jacobson CA; Miklos DB; Lekakis LJ; Oluwole OO; Lin Y; Braunschweig I; Hill BT; Timmerman JM; Deol A; Reagan PM; Stiff P; Flinn IW; Farooq U; Goy A; McSweeney PA; Munoz J; Siddiqi T; Chavez JC; Herrera AF; Bartlett NL; Wiezorek JS; Navale L; Xue A; Jiang Y; Bot A; Rossi JM; Kim JJ; Go WY; Neelapu SS
Lancet Oncol; 2019 Jan; 20(1):31-42. PubMed ID: 30518502
[TBL] [Abstract][Full Text] [Related]
54. Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma.
Wright CM; LaRiviere MJ; Baron JA; Uche C; Xiao Y; Arscott WT; Anstadt EJ; Barsky AR; Miller D; LaRose MI; Landsburg DJ; Svoboda J; Nasta SD; Gerson JN; Barta SK; Chong EA; Schuster SJ; Paydar I; Maity A; Plastaras JP
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):178-188. PubMed ID: 32446950
[TBL] [Abstract][Full Text] [Related]
55. Lymphodepletion chemotherapy revitalizes chimeric antigen receptor T cells contributing to regression of relapsed B-cell lymphoma: A case report.
Liang Z; Zhang H; Shao M; Cui Q; Wu Z; Xiao L; Huang H; Hu Y
Medicine (Baltimore); 2020 Oct; 99(43):e22510. PubMed ID: 33120740
[TBL] [Abstract][Full Text] [Related]
56. Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: A real-world study.
Iovino L; Wu QV; Voutsinas J; Panaite L; Mullane E; Lynch RC; Ujjani C; Smith SD; Gopal AK; Till BG; Milano F; Chow V; Gauthier J; Turtle CJ; Maloney DG; Shadman M
J Cell Mol Med; 2022 Dec; 26(24):5976-5983. PubMed ID: 36453136
[TBL] [Abstract][Full Text] [Related]
57. Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma.
Wu J; Cao Y; Zhang Q; Liu W; Zhou X; Ming X; Meng F; Zhang Y; Li C; Huang L; Wei J; Zheng M; Zhang S; Zhang T; Zhu X; Wang N; Wang J; Wang G; Zhou J; Liu B; Xiao Y
Front Immunol; 2022; 13():879983. PubMed ID: 35669773
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
[TBL] [Abstract][Full Text] [Related]
59. Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma.
Mirza AS; Kumar A; Hashmi H; Garcia F; Logothetis CN; Darwin A; Faramand R; Reid K; Bachmeier C; Chavez JC; Shah B; Pinilla-Ibarz J; Khimani F; Lazaryan A; Liu H; Davila ML; Nishihori T; Locke FL; Jain MD
Transplant Cell Ther; 2021 Mar; 27(3):242.e1-242.e6. PubMed ID: 33781520
[TBL] [Abstract][Full Text] [Related]
60. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
